Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3101-3120 of 3,900 trials

Head and Neck Cancer: Niraparib and Dostarlimab Study

We are studying the effects of Niraparib and Dostarlimab combined with chemotherapy and radiotherapy in patients with locally advanced head and neck cancer. The goal is to see if this combination improves treatment outcomes compared to standard approaches.

Squamous Cell Carcinoma of the Head and Neck>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Preventing Infections in ICU Patients with Interferon Gamma

We are studying whether interferon gamma can help prevent secondary infections in ICU patients with weakened immune systems. This research may improve recovery and reduce hospital stays.

Sustained Immunosuppression>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInfectious DiseasesInternal MedicinePulmonology

HER2-Targeting Imaging for Cancer Patients

We are testing a new imaging method using a special drug to help identify HER2-positive tumors in cancer patients. This may improve how we detect and monitor cancer.

Breast Cancer and Gastroesophageal AdenocarcinomaSafety phase (I)Oncology

Stage IV NSCLC: Osimertinib with Chemotherapy

We are studying the combination of osimertinib and chemotherapy for patients with stage IV non-small cell lung cancer who have atypical EGFR mutations. The goal is to evaluate its effectiveness, safety, and impact on quality of life.

Stage IV Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Diffuse Large B-Cell Lymphoma: Glofitamab with Gemcitabine and Oxaliplatin

We are studying a new treatment combination for patients with relapsed or refractory diffuse large B-cell lymphoma. The focus is on understanding the safety and frequency of cytokine release syndrome with this therapy.

Refractory Diffuse Large B-Cell Lymphoma6-12 monthsEfficacy phase (II)>20 visitsPartially RemoteHematologyOncology

Metastatic Non-Small Cell Lung Cancer: Visugromab Treatment

We are studying whether visugromab, combined with standard chemotherapy, can improve outcomes for patients with metastatic non-squamous non-small cell lung cancer. The trial also looks at safety and quality of life during treatment.

Metastatic Non-Squamous Non-Small Cell Lung CancerEfficacy phase (II)Investigational MedicinesPartially RemoteOncology

Metastatic Non-Squamous Non-Small Cell Lung Cancer: Visugromab and Nivolumab Study

We are investigating whether a new treatment combining visugromab and nivolumab with or without docetaxel can improve outcomes for patients with metastatic non-squamous non-small cell lung cancer. This study will help us understand its effectiveness and safety compared to standard treatments.

Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Investigational MedicinesPartially RemoteOncology

HPV-Negative Head and Neck Cancer: PARP Inhibitor and Immunotherapy Study

We are investigating a new treatment combining a PARP inhibitor and immunotherapy for patients with HPV-negative head and neck cancer. The study aims to see how well this treatment works and its safety compared to standard options.

Oropharyngeal Squamous Cell CarcinomaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Metastatic Colorectal Cancer: Arfolitixorin Combination Therapy

We are studying a new treatment combining arfolitixorin with standard drugs for patients with metastatic colorectal cancer. The goal is to evaluate its safety and effectiveness in improving treatment results.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Alagille Syndrome: Long-Term Study of Livmarli

We are examining the long-term safety and effectiveness of Livmarli in patients with Alagille Syndrome. This study will help us understand how well the treatment works and its tolerability over time.

Alagille Syndrome>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyHepatologyInternal Medicine

Nivolumab for ALK+ Anaplastic Large Cell Lymphoma

We are studying the effects of nivolumab in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma. This trial looks at its effectiveness for those with progressive disease and as a follow-up treatment for those in remission.

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Head and Neck Cancer: Nivolumab and Ipilimumab Study

We are studying the effects of nivolumab alone and in combination with ipilimumab after surgery for head and neck cancer. This trial aims to see if these treatments can help patients stay cancer-free and how they affect quality of life.

Head and Neck Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Parkinson's Disease: CVN424 Study

We are testing a new medication, CVN424, for people with Parkinson's disease to see if it helps reduce OFF time and improve overall motor function. The study also aims to evaluate its safety and effects on quality of life.

Parkinson's Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Chronic Rhinosinusitis with Nasal Polyps: Itepekimab Study

We are investigating whether itepekimab can help adults with chronic rhinosinusitis and nasal polyps by reducing polyp size and nasal congestion. This study will also look at its effects on overall symptoms and quality of life.

Chronic Rhinosinusitis with Nasal PolypsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOtolaryngologyPulmonology

Advanced Solid Tumors: MK-3120 Treatment Study

We are testing a new treatment called MK-3120 for people with advanced solid tumors to see how safe it is and if it can help reduce tumor size.

Advanced Solid Tumor Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

CAR-T Cell Therapy for Autoimmune Diseases

We are studying a new CAR-T cell treatment for patients with active autoimmune diseases like lupus, systemic sclerosis, and inflammatory myopathy. The trial aims to assess safety and how well this therapy works in reducing disease symptoms.

Systemic SclerosisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathy6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyNeurologyRheumatology

Hypochondroplasia: Infigratinib for Growth

We are investigating whether infigratinib can help children aged 3 to 11 with hypochondroplasia grow taller and improve their overall health. The study will also look at the safety of this new treatment.

Hypochondroplasia>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

Baricitinib for Children Hospitalized with COVID-19

We are studying how the medication baricitinib works in children aged 1 to under 18 years who are hospitalized with COVID-19. This research aims to ensure the safety and proper dosing for young patients.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

CD19+ Lymphoid Disease: CAR T-Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory CD19+ lymphoid diseases like leukemia and lymphoma. The goal is to see if this approach can safely reduce cancer and improve patient outcomes.

Acute Lymphoblastic Leukemia (ALL) RecurrentNon-Hodgkin's Lymphoma (NHL) Refractory>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Triple-Negative Breast Cancer: Sacituzumab Tirumotecan Study

We are studying a new treatment for people with previously untreated triple-negative breast cancer. This trial compares a new drug alone and with another medication against standard treatment to see which works better.

Triple Negative Breast Cancer (TNBC)>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementGynecology and ObstetricsOncology